LAG3 and head and neck squamous cell carcinoma: Novel ICIs targeting checkpoints beyond PD-1 (such as LAG-3 or TIGIT) may soon yield phase III data; a successful outcome could lead to the first dual-checkpoint regimen approved in HNSCC.